Genitourinary Cancers

The phase III HYPRO study failed to prove the non-inferiority of using hypofractionated radiotherapy compared with fractionated radiotherapy for late genitourinary and gastrointestinal toxicity in men with intermediate- or high-risk prostate cancer.

A 58-year-old man presents with symptoms of dysuria and a prostate biopsy is performed. What is your diagnosis?

The American Society of Clinical Oncology endorsed the European Association of Urology’s treatment guideline on muscle-invasive and metastatic bladder cancer.

The US Food and Drug Administration has accepted the priority application for atezolizumab (MPDL3280A), an investigational targeted agent for patients with locally advanced or metastatic urothelial carcinoma.

This article provides a comprehensive and up-to-date review of the role of HPV infections in men and in the development of penile cancer.

Our commentary aims to expand on the evolution and present state of the art in the pathology of HPV in penile cancer and precancerous lesions.

Over the past 5 years, several studies have investigated the molecular profiling of penile carcinomas, examining both genomic and epigenetic alterations. These studies have revealed distinct molecular pathways associated with HPV status.

Men who receive radiation therapy as treatment for their prostate cancer may have an increased risk of developing a secondary cancer, according to a meta-analysis of observational studies.

Analyses from the phase III ALSYMPCA trial showed that treatment with radium-223 resulted in quality-of-life improvements over placebo in patients with castration-resistant prostate cancer and symptomatic bone metastases.

The addition of ramucirumab to docetaxel improved progression-free survival compared with docetaxel alone in a randomized phase II trial of patients with locally advanced or metastatic urothelial carcinoma.

In light of the recent announcement by Vice President Joe Biden to infuse the US cancer research program with $1 billion, a so-called “Moon Shot” program, we are speaking today with Giulio Draetta, a clinician and cancer researcher at MD Anderson Cancer Center at the University of Texas in Houston, who leads that center’s Moon Shots program.

A panel of experts at the ASCO have reviewed and endorsed Cancer Care Ontario’s guideline on Active Surveillance for the Management of Localized Prostate Cancer.

Abituzumab did not extend progression-free survival in patients with castration-resistant prostate cancer, though it did improve bone lesion progression.

We present a joint perspective from the medical oncology and urologic disciplines on the ongoing efforts to advance clinical trial performance in order to discover new therapies for this fatal disease.

The great strength of the PCWG3 is the recognition that second- , third- , and fourth-line treatments offer new possibilities for extending overall survival.

The 2012 change in guidelines regarding PSA testing for prostate cancer had a different effect on testing rates depending on which physician specialty was doing the testing.

A 23-year-old young man presents with a testicular lesion. After assessing the lesion, a biopsy is performed. What is your diagnosis?

In this interview we discuss predictive biomarkers and response to immune checkpoint inhibitors for urothelial tumors, which include tumors of the bladder, ureters, and the renal pelvis.

Combined use of systematic and targeted magnetic resonance-ultrasound–guided fusion biopsy was effective in diagnosing clinically significant prostate cancer.

A study found that about half of advanced germ cell tumor patients with platinum-resistant or -refractory disease harbor potentially actionable mutations.

An observational study found that adjuvant chemotherapy improves overall survival in patients with locally advanced bladder cancer.

A 55-year-old Hispanic male presents with a family history of gastric cancer in one sibling and prostate cancer in an older brother. CT performed in March 2015 for IMT surveillance showed a heterogeneous prostate with local invasion involving the bladder, seminal vesicles, and perirectal fat.

Despite a high rate of hematologic toxicity, combined low-dose gemcitabine (Gemzar), paclitaxel, and sorafenib (Nexavar) showed promise as a well-tolerated salvage therapy in a small group of patients with cisplatin-resistant urothelial cancer.

BRCA mutations and co-occurring gene alterations in prostate cancer suggest that some patients might benefit from oral poly (ADP-ribose) polymerase (PARP) inhibitors.

Results from the large STAMPEDE trial suggest that the combination of zoledronic acid and celecoxib along with standard of care could improve failure-free survival in prostate cancer patients starting hormone therapy whose disease has metastasized.

The combination of the novel histone deacetylase inhibitor entinostat and high-dose interleukin-2 yielded a promising response rate in patients with metastatic renal cell carcinoma.

The anti-PD-L1 antibody atezolizumab showed significantly improved objective response rates compared to historic controls in a phase II study of patients with locally advanced or metastatic urothelial carcinoma previously treated with platinum-based therapy.

A hypofractionated radiotherapy regimen was found to be noninferior to conventional fractionation for low-risk prostate cancer patients in a new randomized phase III trial.

A meta-analysis found that radiotherapy for prostate cancer is associated with worse overall and prostate cancer–specific survival compared with surgery.

A new study has confirmed the safety and efficacy of pazopanib in a real-world setting of patients with metastatic renal cell carcinoma (mRCC) and validates the International Metastatic Renal Cell Carcinoma Database (IMDC) prognostic model in this patient population.